EVENITY ™ (romosozumab-aqqg) now available in the United States for the treatment of osteoporosis in postmenopausal women at high risk for fracture
Amgen (NASDAQ: AMGN) announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture. (Source: World Pharma News)
Source: World Pharma News - April 16, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Amgen sets $21,900 annual price for new Evenity bone drug
Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

EVENITY ™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
New Therapy to Cost One-Third Less Than Other Bone-Building Agents Over Full Course of Therapy THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture. "Osteoporosis is a silent disease that can lead to devastating consequences. Unfortunately, only 20 percent of women who have experienced a fracture receive any...
Source: Amgen News Release - April 15, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Drink up: Beer is full of dietary silicon that can lower your risk of osteoporosis
(Natural News) There is no question that drinking too much alcohol is bad for your health, but if you avoid it entirely, you could be missing out on some potential health benefits. You’ve probably seen plenty of headlines about the antioxidants in red wine, but if you’ve been looking for an excuse to drink more... (Source: NaturalNews.com)
Source: NaturalNews.com - April 15, 2019 Category: Consumer Health News Source Type: news

Personal Health: After a Hip Fracture, Reducing the Risk of a Recurrence
Following a fracture, patients should have a bone density test, evaluation of calcium and vitamin D levels and, in nearly all cases, medication to protect against further bone loss. (Source: NYT Health)
Source: NYT Health - April 15, 2019 Category: Consumer Health News Authors: JANE E. BRODY Tags: Bone Fractures Hips Bones Falls Osteoporosis Source Type: news

Newly Approved Osteoporosis Drug Is'Promising' and'Welcome'Newly Approved Osteoporosis Drug Is'Promising' and'Welcome '
With the recent FDA approval of romosozumab for the treatment of osteoporosis, Dr Joy Wu discusses its risks and benefits, as well as how it fits in among the other treatment options.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Parathyroid hormone receptor complex mapped with molecular resolution
Research, published inScience, has mapped the molecular complex of parathyroid hormone receptor 1 and could be useful in the development of  improved treatments for osteoporosis and cancer.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 12, 2019 Category: Endocrinology Source Type: news

FDA approves EVENITY ™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture. (Source: World Pharma News)
Source: World Pharma News - April 12, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

The association between osteoporosis and grip strength and skeletal muscle mass in community-dwelling older women - Taniguchi Y, Makizako H, Kiyama R, Tomioka K, Nakai Y, Kubozono T, Takenaka T, Ohishi M.
This cross-sectional study investigated the association between osteoporosis, grip strength, and skeletal muscle mass in community-dwelling older women. Data obtained from 265 older women who participated in a community-based health check survey (Tarumizu ... (Source: SafetyLit)
Source: SafetyLit - April 11, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

FDA Approves New Osteoporosis Treatment
Evenity, an injected therapy, helps build new bone by blocking the effect of a protein called sclerostin. It’s intended for use only in women at high risk off fracture. (Source: WebMD Health)
Source: WebMD Health - April 11, 2019 Category: Consumer Health News Source Type: news

USC research shows remedy for painful jaw disease
(University of Southern California) USC researchers and collaborators report a breakthrough to prevent osteonecrosis of the jaw, a side effect suffered by some people undergoing treatment for cancer or osteoporosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2019 Category: International Medicine & Public Health Source Type: news

Near-atomic map of parathyroid hormone complex points toward new therapies for osteoporosis
(Van Andel Research Institute) An international team of scientists has mapped a molecular complex that could aid in the development of better medications with fewer side effects for osteoporosis and cancer. The near-atomic resolution images depict parathyroid hormone receptor-1 (PTH1R), a molecule that conveys signals to and from cells, interacting with two key messengers -- a molecule that mimics parathyroid hormone, one of the most important regulators of calcium levels in the body, and a stimulatory G protein, a molecule that mediates bone turnover. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 11, 2019 Category: Biology Source Type: news

Structure and dynamics of the active human parathyroid hormone receptor-1
The parathyroid hormone receptor-1 (PTH1R) is a class B G protein–coupled receptor central to calcium homeostasis and a therapeutic target for osteoporosis and hypoparathyroidism. Here we report the cryo–electron microscopy structure of human PTH1R bound to a long-acting PTH analog and the stimulatory G protein. The bound peptide adopts an extended helix with its amino terminus inserted deeply into the receptor transmembrane domain (TMD), which leads to partial unwinding of the carboxyl terminus of transmembrane helix 6 and induces a sharp kink at the middle of this helix to allow the receptor to couple with G ...
Source: ScienceNOW - April 11, 2019 Category: Science Authors: Zhao, L.-H., Ma, S., Sutkeviciute, I., Shen, D.-D., Zhou, X. E., de Waal, P. W., Li, C.-Y., Kang, Y., Clark, L. J., Jean-Alphonse, F. G., White, A. D., Yang, D., Dai, A., Cai, X., Chen, J., Li, C., Jiang, Y., Watanabe, T., Gardella, T. J., Melcher, K., Wa Tags: Biochemistry, Cell Biology r-articles Source Type: news

Amgen wins approval for osteoporosis drug — but with strict warnings
The FDA has greenlighted Amgen ’s new osteoporosis drug for postmenopausal women (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 10, 2019 Category: Pharmaceuticals Source Type: news

FDA approves osteoporosis shot that rebuilds bones at the same rate a teenager's skeleton grows 
On Tuesday, the FDA approved Evenity, the brand name for a drug that can make older women's bones regrow at rates seen in teenagers and cut their risk of spinal fractures by up to 73 percent. (Source: the Mail online | Health)
Source: the Mail online | Health - April 10, 2019 Category: Consumer Health News Source Type: news

FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture
The U.S. Food and Drug Administration approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies. (Source: World Pharma News)
Source: World Pharma News - April 10, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA OKs Romosozumab for Postmenopausal Osteoporosis FDA OKs Romosozumab for Postmenopausal Osteoporosis
Romosozumab should be reserved for women at high risk for fracture who fail other therapies and should be avoided in women with a history of heart attack or stroke.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 10, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Evenity for Osteoporosis
Evenity (romosozumab-aqqg) has been approved to treat postmenopausal women at high risk of bone fractures. (Source: ConsultantLive)
Source: ConsultantLive - April 10, 2019 Category: Internal Medicine Authors: Valerie DeBenedette Tags: New Products Source Type: news

FDA approves new osteoporosis drug for postmenopausal women
The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures. (Source: CNN.com - Health)
Source: CNN.com - Health - April 10, 2019 Category: Consumer Health News Source Type: news

FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture
April 9, 2019 -- The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 9, 2019 Category: Drugs & Pharmacology Source Type: news

Amgen's postmenopausal osteoporosis drug gets FDA greenlight
The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture. (Source: Reuters: Health)
Source: Reuters: Health - April 9, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Most Osteoporosis Drugs Don ’ t Build Bone. This One Does.
In clinical trials, Evenity substantially increased bone density and prevented fractures more effectively than available treatments, according to the drug makers ’ findings. (Source: NYT Health)
Source: NYT Health - April 9, 2019 Category: Consumer Health News Authors: GINA KOLATA Tags: Osteoporosis Bisphosphonates (Drugs) Bones Drugs (Pharmaceuticals) Bone Fractures UCB Amgen Inc Food and Drug Administration Rosen, Clifford J Source Type: news

FDA Approves EVENITY ™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1) EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2) EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2) THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk fo...
Source: Amgen News Release - April 9, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture
FDA approves a new treatment for osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 9, 2019 Category: American Health Source Type: news

FDA Approves Osteoporosis Tx for High-Risk Postmenopausal Women
TUESDAY, April 9, 2019 -- Evenity (romosozumab-aqqg) was approved for the treatment of osteoporosis in postmenopausal women with a high risk for fracture, the U.S. Food and Drug Administration announced. Evenity, a monoclonal antibody, blocks the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2019 Category: Pharmaceuticals Source Type: news

Evenity Approved for Osteoporotic Women
TUESDAY, April 9, 2019 -- Evenity (romosozumab) injection has been approved by the U.S. Food and Drug Administration to treat osteoporosis in postmenopausal women at high risk of breaking a bone, the agency said Tuesday in a news release. More than... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2019 Category: General Medicine Source Type: news

FDA Approves New Osteoporosis Treatment, Evenity (Romosozumab)
TUESDAY, April 9, 2019 -- Many aging Americans face the risk of fractures due to osteoporosis. Now, they have a new means of fighting back, thanks to the U.S. Food and Drug Administration's approval of a new treatment on Tuesday. The FDA gave its... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2019 Category: General Medicine Source Type: news

FDA Approves New Osteoporosis Treatment Evenity (romosozumab)
TUESDAY, April 9, 2019 -- Many aging Americans face the risk of fractures due to osteoporosis. Now, they have a new means of fighting back, thanks to the U.S. Food and Drug Administration's approval of a new treatment on Tuesday. The FDA gave its... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2019 Category: General Medicine Source Type: news

Dr. Shaun Sabico wins the ESCEO-IOF Pierre Meunier Young Scientist Award
(International Osteoporosis Foundation) Dr. Shaun Sabico was presented with the ESCEO-IOF Pierre Meunier Young Scientist Award at a special ceremony held on April 6 at the World Congress on Osteoporosis, Osteoarthritis& Musculoskeletal Disease (WCO-IOF-ESCEO '19 Paris). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2019 Category: International Medicine & Public Health Source Type: news

IOF Medal of Achievement awarded to Harry K. Genant
(International Osteoporosis Foundation) Harry K. Genant, MD, Professor Emeritus of the University of California San Francisco, and Chairman Emeritus of the Board of Directors of Synarc, Inc., has been awarded the prestigious 2019 International Osteoporosis Foundation (IOF) Medal of Achievement. The Award was presented on April 6, 2019 at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Paris, France. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2019 Category: International Medicine & Public Health Source Type: news

IOF President's Award honours exceptional members from Australia and Serbia
(International Osteoporosis Foundation) Dr Radmila Matijevic (ASTAS, Serbia) and Dr Greg Lyubomirsky (Osteoporosis Australia) have been awarded the prestigious International Osteoporosis Foundation (IOF) President's Award. The Award is presented annually to individuals representing IOF member societies, in recognition of their contributions to IOF and their exceptional commitment to advancing education and awareness in the field. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2019 Category: International Medicine & Public Health Source Type: news

Eating sugar substantially increases your risk of osteoporosis
(Natural News) Consumption of sugar has been linked to various health problems, such as diabetes and cancer. New research revealed that consuming refined white sugar can increase your risk of osteoporosis, a condition characterized by brittle bones that easily break. Researchers looked at the effects of table salt and white sugar on the development of... (Source: NaturalNews.com)
Source: NaturalNews.com - April 7, 2019 Category: Consumer Health News Source Type: news

Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe
Study Shows 55 Percent of Women Over 70 Years Old are at Risk of Fragility Fractures With 75 Percent of Them not Treated for Osteoporosis THOUSAND OAKS, Calif., April 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data presented from a cross-sectional study revealing a gap in the diagnosis and treatment of osteoporosis in Europe. The real-world study of osteoporosis management in primary care revealed that 75 percent of female patients aged 70 years and older who were at increased risk of fragility fractures were not treated for osteoporosis. The treatment gap was much lower in those with a recor...
Source: Amgen News Release - April 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

ITP and B-cell Lymphoma Feature in Latest BSH Guidance ITP and B-cell Lymphoma Feature in Latest BSH Guidance
Recommendations on tackling osteoporosis in immune thrombocytopenia and mediastinal B-cell lymphoma management are the latest guidance by the British Society for Haematology in a prolific year.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 5, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

John A. Kanis named winner of IOF Olof Johnell Science Award
(International Osteoporosis Foundation) The 2019 International Osteoporosis Foundation (IOF) Olof Johnell Science Award was presented to Professor John A. Kanis at a ceremony held on April 4 at the opening of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Paris, France. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 5, 2019 Category: Biology Source Type: news

Most Osteoporosis Guidelines Do Not Discuss Patient Choices
THURSDAY, April 4, 2019 -- Less than 40 percent of osteoporosis clinical practice guidelines include any mention of patients'beliefs, values, or preferences (BVPs), according to a study published online March 11 in Osteoporosis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 4, 2019 Category: Pharmaceuticals Source Type: news

Paris hosts the world's largest event dedicated to musculoskeletal disease prevention
(International Osteoporosis Foundation) Today, medical experts and researchers from around the world will gather at the Palais des Congr è s in Paris, France, for the opening of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, the leading clinical Congress dedicated to musculoskeletal health and disease prevention. The Congress takes place from April 4-7, 2019. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2019 Category: International Medicine & Public Health Source Type: news

Genome studies identify new osteoporosis risk genes
Two new genes that may predispose to osteoporosis have been identified using large-scale genomics analysis, and may lead to better future therapies, according to a study published inNature Communications.Medical News Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - March 27, 2019 Category: Endocrinology Source Type: news

NAFLD, Osteoporotic Fractures, and Bone Mineral Density NAFLD, Osteoporotic Fractures, and Bone Mineral Density
To what extent does NAFLD affect osteoporosis and bone health?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 27, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

ENDO: Recommendations Issued for Treating Osteoporosis
TUESDAY, March 26, 2019 -- Recommendations have been developed for the pharmacological management of osteoporosis in postmenopausal women; the clinical practice guideline was published online March 25 in the Journal of Clinical Endocrinology&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 26, 2019 Category: Pharmaceuticals Source Type: news

New Guidelines Address Osteoporosis Treatment Postmenopause New Guidelines Address Osteoporosis Treatment Postmenopause
The Endocrine Society's new guidelines advise bisphosphonates and denosumab as first line for lower-risk women and anabolic treatments as first line for those at very high fracture risk.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 26, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Medical News Today: Osteoporosis: New tools help pinpoint potential risk genes
Genome analysis and 3D DNA studies helped scientists to identify two new genes that impact bone-producing cells to potentially alter osteoporosis risk. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2019 Category: Consumer Health News Tags: Bones / Orthopedics Source Type: news

Osteoporosis and the ageing skeleton - Aspray TJ, Hill TR.
Osteoporosis is a "skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture" which, in light of demographic change, is becoming an increasing burden on health care worldwide. Increasing age and fem... (Source: SafetyLit)
Source: SafetyLit - March 24, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Bisphosphonates increasingly prescribed to the women most likely to benefit
(The Endocrine Society) In recent years, women who start taking bisphosphonates (BPs) to treat osteoporosis and prevent fracture have trended from younger to older and from having osteopenia to having osteoporosis, researchers report. The results of the study will be presented on Saturday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 23, 2019 Category: International Medicine & Public Health Source Type: news

How does estrogen protect bones? Unraveling a pathway to menopausal bone loss
(Tokyo Medical and Dental University) Women who have reached menopause are at a greater risk of developing osteoporosis, which can lead to bone fractures and long-term impairment of mobility. Studies have suggested a link between reduced bone density and low estrogen levels due to menopause, but the basis for this link is unclear. Researchers at Tokyo Medical and Dental University found that the protein Sema3A plays a key role in maintaining healthy bones, suggesting a new therapeutic avenue to treat osteoporosis. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 22, 2019 Category: Biology Source Type: news

Cataract and Risks of Osteoporosis and Fracture Cataract and Risks of Osteoporosis and Fracture
Are individuals with cataract at higher risks of osteoporosis and fracture than those without?Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2019 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Review of osteoporosis clinical practice guidelines finds majority lack patient values
Review included countries such as Australia, Canada, Germany, India, Italy, Scotland, South Africa, Spain, United Kingdom and United States (Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - March 21, 2019 Category: Hospital Management Tags: Hospital News Source Type: news

Research implicates causative genes in osteoporosis, suggesting new targets for future therapy
(Children's Hospital of Philadelphia) Scientists have harnessed powerful data analysis tools and three-dimensional studies of genomic geography to implicate new risk genes for osteoporosis, the chronic bone-weakening condition that affects millions of people. Knowing the causative genes may later open the door to more effective treatments. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 21, 2019 Category: Biology Source Type: news

Review of osteoporosis clinical practice guidelines finds majority lack patient values
(St. Michael's Hospital) Patients' voices are ignored all too often in osteoporosis clinical practice guidelines, say researchers, who reviewed 70 English-language guidelines around the world and found less than 40 percent included any mention of patients' beliefs, values or preferences (BVPs). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2019 Category: International Medicine & Public Health Source Type: news

AAOS: Supplement Use Low in Patients With Osteoporosis, Hip Fracture
FRIDAY, March 15, 2019 -- Of patients diagnosed with osteoporosis who have a history of hip fracture, only 14 percent are receiving appropriate calcium and vitamin D supplementation, according to a study presented at the annual meeting of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 15, 2019 Category: Pharmaceuticals Source Type: news